Switzerland-based pharmaceutical company Novartis announced Tuesday that it has lost its appeal of a competition fine issued by Italian officials for anticompetitive conduct.
According to reports, a regional court in Italy upheld fines issued to Novartis and its rival Roche for anticompetitive conduct; the nation’s Competition Authority sanctioned the companies last March after finding the firms had colluded to prevent market entry of a cancer drug for use as an eye disease treatment. The companies were fined $226 million, reports say.
While the fines were upheld, Novartis still denies the decision. “Novartis firmly rejects the accusations of anticompetitive practices and any allegations of anticompetitive behavior are unfounded and without merit,” the company said in a statement, adding that the company will appeal this decision as well.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI